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Editorial Comment 
Heart Transplant Centers: 
No Longer the End of the Road 
for Heart Failure* 
LYNNE WARNER STEVENSON,  MD, FACC 
Boston, Massachusetts 
Improving survival on medical therapy. The impact of 
medical therapy for advanced heart failure continues to im- 
prove, as demonstrated in the article by Rickenbacher tal. (1) 
from Stanford University, whose experience also emphasizes 
the limited prognostic factors and the critical importance of 
concentrated expertise for this population. No longer are 
patients referred for transplantation given a prognosis of <6 
months to live with their original hearts. With this and other 
recent experience, we have now passed far beyond the study 
that concluded in 1985 that patients initially considered "too 
well" for transplantation subsequently deteriorated and died 
(2), without the meticulous follow-up and reevaluation that 
have since been recognized as a pivotal component of success- 
ful outcome, with or without transplantation. Even patients 
discharged after presenting for transplantation with New York 
Heart Association functional class IV symptoms have recently 
been shown to have a 1-year survival of 68% (3), compared 
with the earlier 54% described in 1987 for the enalapril group 
of the CONSENSUS trial (4) in patients with less clinical 
compromise. 
The Stanford center's experience of 116 patients with mean 
peak oxygen uptake (Vo2) of 17 ml/kg per rain confirms 
reports by Mancini et al. (5) and Stevenson (6) that potential 
transplant candidates with peak V% >12 to 14 ml/kg per rain 
have good 1- to 2-year survival without transplantation. The 
current report provides further follow-up >2 years for a 
sizeable group of patients eligible for transplantation, demon- 
strating the continued similarity to results after transplanta- 
tion, although transplantation still provides better late survival 
(60% to 70% at 5 years, 45% at 10 years [7]). This group of 
patients hould not expect significant improvement in func- 
tional capacity after transplantation, at least as measured by 
peak Vo2, which remains in the range of 50% to 70% of 
predicted normal values after transplantation. A randomized, 
controlled trial between transplantation and medical therapy 
has been suggested for patients with peak Vo2 >13 ml/kg per 
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min, but such a trial is unlikely to occur in the current era, as 
defined by 1) the priority of more critically ill patients for 
limited donor hearts, and 2) the guidelines from both the 
Bethesda Conference (8) and the Consensus Conference on 
Candidate Selection (9) suggesting that transplantation is not 
often indicated for patients with peak Vo2 >14 ml/kg per rain. 
Identification of high and low risk patients. There are 
extensive published reports addressing the risk factors for poor 
outcome in heart failure. Many risk factors validated in the 
broad spectrum of mild to moderate heart failure are uni- 
formly elevated and are thus poor discriminants in advanced 
heart failure. As presented inthe report by Rickenbacher tal. 
(1) and others, attempts to define a population at particularly 
low risk may be more relevant o the evaluation of individual 
ambulatory candidates for heart transplantation. This reports 
the successful integrated ecision process of an experienced 
transplant center, but their success cannot be translated into 
guidelines by which effective selection could be made with less 
experience. However, it is not necessarily desirable that selec- 
tion for transplantation take place without extensive xperi- 
ence. 
Having already defined a group at relatively low risk using 
multiple factors, Rickenbacher t al. then searched for factors 
within that group that would predict higher isk among the low 
risk patients. The small numbers of end points (eight cardiac 
deaths, eight later listings for transplantation) limit attempts to 
validate these risk factors. The variables of longer symptom 
duration and elevated pulmonary pressures predicted need for 
transplantation but also could have contributed to the decision 
regarding need for transplantation. The lack of contribution of 
peak Vo2, in contrast o other reports, probably reflects its 
contribution to selection of the original cohort with an average 
peak Vo 2 of 17 + 4 ml/kg per rain, which would predict a 
favorable outcome. Multiple other prognostic factors have 
been proposed in the population with advanced heart failure 
(Table 1). Once left ventricular ejection fraction is <30% and 
heart failure is advanced, the measured value of left ventricular 
ejection fraction has not been predictive in the Rickenbacher 
et al. or most other recent studies, although some controversy 
exists. Right ventricular function is less uniformly compro- 
mised and may in future be found to confer more prognostic 
information (10). 
This and multiple recent studies emphasize the importance 
of serial evaluation of patients after initial referral, at which 
time their condition may reflect more the vigor of previous 
therapy than the underlying capacity for compensation. The 
Bethesda Conference summary describes the need for aggres- 
sive therapy with combinations of vasodilator and diuretic 
drugs before assessment of indications for transplantation, 
indicating that "therapy should be adjusted until clinical 
congestion has been resolved or until further therapy has been 
repeatedly limited by severe hypotension (generally systolic 
blood pressure <80 mm Hg) or marked azotemia" (8). It is 
further emphasized that "Patients hould not be considered to 
have refractory hemodynamic decompensation u til therapy 
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Table 1. Partial List of Proposed Prognostic Factors in Ambulatory 
Candidates for Heart Transplantation 
Common prognostic factors 
Clinical status 
New York Heart Association functional class 
Criteria of stability 
Peak oxygen consumption 
Demonstrable improvement or deterioration 
Left ventricular dimension 
Right ventricular function 
Atrioventricular regurgitation 
Pulmonary pressures/filling pressures on optimal therapy 
Systemic blood pressure 
Serum sodium concentration 
Ability to take angiotensin-converting e zyme inhibitors 
Factors predictive in some series 
Etiology of disease 
Duration of disease 
Left ventricular ejection fraction 
Cardiac index 
Serum catecholamine levels 
History of symptomatic/asymptomatic arrhythmias 
Factors with limited information 
Degree of myocardial fibrosis 
Atrial natriuretic peptide levels 
Endothelin levels 
Oytokine levels 
MIBG imaging of myocardium 
Reduced ratio of tri-iodothyronine/reverse tri-iodothyronine 
Abnormal findings on signal-averaged lectrocardiogram 
Numerous others described in small series 
MIBG = metaiodobenzylguanidine. 
with intravenous followed by oral vasodilator and diuretic 
agents has been pursued using continuous hemodynamic mon- 
itoring to approach hemodynamic goals." In the approach 
presented by Rickenbacher tal., the 18% of referred patients 
ultimately classified as "too well" achieved similar hemody- 
namic and clinical goals through serial outpatient adjustments 
of therapy. Whether more aggressive inpatient herapy could 
have restored stabilization in any of the 35% of their patients 
initially listed for transplantation or the 25% of patients 
rejected for transplantation is not known. 
One of the strongest predictors of good outcome may be 
improvement after referral (11). A minority of patients may 
actually have spontaneous improvement of left ventricular 
function as a result of resolution of cardiomyopathy of rela- 
tively recent onset, recent viral illness exacerbating left ven- 
tricular dysfunction of another cause or abstention from heavy 
alcohol consumption. These patients may need to be identified 
and followed up differently than those with a stable low 
ejection fraction (12). However, even without major improve- 
ment in left ventricular ejection fraction, clinical improvement 
frequently occurs, as defined by criteria for freedom from 
congestion, increase in peak Voe or improvement in the global 
assessment of quality of life, as discussed in the report by 
Rickenbacher t al. 
In an earlier era of transplantation a d medical therapy, the 
"wait and see" strategy of selection was shadowed by the 
relatively high risk of sudden death early after referral. Al- 
though sudden death continues to account for up to 50% of 
mortality in many studies and all of the mortality in the present 
study (1), the absolute incidence has decreased. The increasing 
use of angiotensin-converting e zyme inhibitors, the avoidance 
of class I antiarrhythmic agents and perhaps increasing use of 
amiodarone appear to have contributed to the improved 
survival in advanced heart failure. In a recent longitudinal 
study of 737 patients referred for transplantation (13), the 
1-year isk of sudden death on medical therapy declined from 
20% before 1988 to 8% after 1990. It should be recognized that 
some of the decrease in sudden death may also result from the 
closer surveillance and improving ability to recognize and 
address early signs of recurrent hemodynamic decompensa- 
tion. The most common adverse vent after the first 6 months 
is no longer death; rather, it is deterioration to the point of 
requiring urgent ransplantation (14). In this and other expe- 
rience, such deterioration is not associated with a worse 
posttransplant outcome but will increase overall hospital costs. 
Heart failure/transplant centers--new destinations. The 
increasing success of transplantation has attracted large num- 
bers of patients with advanced heart failure. Although these 
potential candidates have come to transplant centers as "the 
end of the road," the supply of donor hearts cannot begin to 
match the need. Approaches originally developed just to keep 
patients going until transplantation have now evolved to 
provide alternate routes for many patients to defer or even 
avoid transplantation. A vital component of the success of 
every program has been the recognition that the same invest- 
ment in facilities and personnel necessary for a successful 
transplant program or clinical trial program is necessary for 
optimal care of all patients with advanced heart failure. It is 
particularly encouraging in this financially constrained system 
that cost savings can be demonstrated for potential transplant 
candidates in terms of up to an 80% decrease in hospital 
admissions for heart failure after referral to a transplant center 
(15). Such savings might be extended by referral of patients 
after the first hospital admission rather than waiting until heart 
failure appears to be "end-stage." Decreased cost and im- 
proved quality of life also resulted from specialized interven- 
tion in elderly patients with milder heart failure (16). 
In current practice, patients are seldom referred for care of 
heart failure unless transplantation is considered to be an 
eventual option. However, should the benefits of heart failure/ 
transplant centers be restricted to potential candidates for 
transplantation? There will be -2,400 patients receiving a 
heart transplant this year, whereas > 1 million patients will be 
admitted to the hospital with heart failure. For the majority of 
these patients who are beyond the age limit for heart trans- 
plantation, there is currently little opportunity to benefit from 
the lessons learned at heart failure/transplant centers. The 
most important new mission of the dedicated heart failure/ 
transplant centers may be to offer measurably better quality of 
life to the growing populations of patients with heart failure for 
whom transplantation will never be an option. 
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